Paule Augereau

Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort

Amélie Darlix, G. Louvel, Julien Fraisse et al. · British Journal of Cancer · 2019 · 221 citations · Full text

Medicine, Oncology, Breast Oncology +15

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer

Pierre‐Etienne Heudel, Jean‐Sébastien Frenel, Cécile Dalban et al. · JAMA Oncology · 2022 · 79 citations · Full text

Medicine, Oncology, Pharmacology +16

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer

C. Domergue, E. Martin, Camille Lemarié et al. · Cancers · 2022 · 65 citations · Full text

Medicine, Oncology, Breast Oncology +14